The drug reduced luteinizing hormone (LH) in females with polycystic ovary syndrome [6], follicle-stimulating hormone (FSH) in women after menopause [7], and both FSH and LH in males with hypergonadotropic hypogonadism [8]. This evidence concerns the gene BRD2 and polycystic ovary syndrome.